CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Divi's Laboratories Ltd (Parent) is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Divi's Laboratories Ltd (Parent)
1-72/23(P)/Divis/303
, Divi Towers, Cyber Hills, Gachibowli,
Phone: +91 4023786300p:+91 4023786300 HYDERABAD, 500032  India Fax: +91 4023786460f:+91 4023786460
Business Summary
Divi's Laboratories Limited is an India-based company, which is engaged in manufacturing and sale of active pharmaceutical ingredients (APIs), intermediates and nutraceutical ingredients with predominance in exports. The Company’s products include Bupropion HCl, Capecitabine, Carbidopa, Diltiazem HCl, Dextromethorphan Base, Dextromethorphan HBr, Gabapentin, Iopamidol, Iohexol, Irbesartan, Lacosamide, Levetiracetam, Levodopa, Losartan, Nabumetone, Naproxen, Naproxen Sodium, Olmesartan Medoxomil, Pregabalin, Ticagrelor, Triprolidine HCl, Valacyclovir HCl, Valsartan, Venlafaxine HCl and Vigabatrin. In addition to generic business, the Company, through its custom synthesis business, supports pharma companies for their patented products business right from gram scale requirements for clinical trials to launch, as well as late life cycle management. The Company’s subsidiaries include Divis Laboratories (USA) Inc. and Divi’s Laboratories Europe AG.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Non-Executive Independent Chairman of the Board Ramesh B.Nimmagadda 4/1/2020 6/22/2017
Chief Executive Officer, Whole-time Director Kiran S.Divi 46 1/4/2020
Chief Financial Officer L. KishoreBabu 73 1/1/2010 1/1/2010
8 additional Officers and Directors records available in full report.

Business Names
Business Name
M/s. Divi’s Laboratories Europe AG.
M/s. Divis Laboratories (USA) Inc.

General Information
Outstanding Shares: 265,468,580 (As of 3/31/2023)
Shareholders: 39,603
Fax Number: +91 4023786460


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, September 27, 2023